NAD augmentation as a disease-modifying strategy for neurodegeneration.
NAD augmentation as a disease-modifying strategy for neurodegeneration.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Bergen, NO · Author affiliation
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway; Department of Clinical Medicine, University of Bergen, Pb 7804, 5020 Bergen, Norway; K.G. Jebsen Center for Translational Research in Parkinson's Disease, University of Bergen, Pb 7804, 5020 Bergen, Norway. Electronic address: christian.doelle@uib.no.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Neurodegenerative diseases (NDDs) pose a significant and rapidly growing global health challenge, but there are no effective therapies to delay or halt progression. In recent years augmentation of nicotinamide adenine dinucleotide (NAD) has emerged as a promising disease-modifying strategy that targets multiple key disease pathways across multiple NDDs, such as mitochondrial dysfunction, energy deficits, proteostasis, and neuroinflammation. Several early clinical trials of NAD augmentation have been completed, and many more are currently underway, reflecting the growing optimism and urgency within the field. We discuss the rationale and evolving therapeutic landscape of NAD augmentation. We argue that, to fully realize its therapeutic potential, it is essential to determine the specific contexts in which NAD supplementation is most effective and to address crucial knowledge gaps.